Telomir Pharmaceuticals, Inc. Common Stock
$1.48
+0.0000%Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.0).
Valuation inputs: P/E -4.0, earnings yield N/A, momentum 0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.8%, ROIC -1.8%).
Profitability stack: net margin 0.0%, ROE -1.8%, ROIC -1.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +19.5%, momentum 0.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Telomir Pharmaceuticals, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Telomir Pharmaceuticals, Inc. Common Stock Fair Value Envelope
No Revenue Data
TELO has not reported any revenue values in the available annual periods.
Telomir Pharmaceuticals, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
TELO has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
TELO has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
TELO has not reported any net profit margin values in the available annual periods.
Telomir Pharmaceuticals, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Telomir Pharmaceuticals, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Telomir Pharmaceuticals, Inc. Common Stock Street Expectations Map
No Target Data
No analyst price targets available for telo.
Telomir Pharmaceuticals, Inc. Common Stock Insider Positioning
During the last 12 months, there has been no insider trading activity reported for TELO.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
No Dividend Yield Data
TELO has not reported any dividend yield values in the available annual periods.
telo Dividend History
Learning Layer
Related Guides
Build conviction on TELO by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.